VEMURAFENIB 240 MG TABLETS
ZELBORAF (vemurafenib) is a kinase inhibitor available as 240 mg tablets for oral use. Tablets of ZELBORAF are for oral administration. Each tablet contains 240 mg of vemurafenib. 281 The inactive ingredients of ZELBORAF are: Tablet core: hypromellose acetate succinate, croscarmellose 282 sodium, colloidal silicon dioxide, magnesium stearate, and hydroxypropyl cellulose. Coating: pinkish 283 white: poly (vinyl alcohol), titanium dioxide, polyethylene glycol 3350, talc, and iron oxide red.
ZELBORAF (vemurafenib) Tablet: 240 mg
Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with ZELBORAF. Recommended dosage: 960 mg orally twice daily taken approximately 12 hours apart with or without a meal.
ZELBORAF (vemurafenib)is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma.